Gujarat Kidney And Super Speciality profit and loss

Latest FY26

Revenue: ₹82.0cr
EBITDA: ₹26.9cr
Net profit: ₹16.8cr
EPS: ₹2.49

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026

Expenses
	101	82.0
	1.6	0.9
	103	82.9
	12.1	9.1
	16.8	13.6
	2.4	1.9
	5.2	4.7
	45.4	32.3
	81.9	61.7
	26.7	26.9
	21.5	22.2
Profit
	20.7	21.2
	20.7	21.2
	4.8	5.2
	−0.9	−0.8
	4.0	4.4
	16.7	16.8
	16.7	16.8
	0.2	−0.0
	16.9	16.8
	15.8	15.5
	1.3	1.3
Per share
	₹2.51	₹2.49
	₹2.51	₹2.49
Other comprehensive income — detail
	0.2	−0.0
	—	0.1
	0.0	0.1
	16.0	15.4
	1.3	1.3
Per share — as-filed variants
	₹2.51	₹2.49
	₹2.51	₹2.49
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	89.0	72.9
	88.1%	88.9%
Adjusted (ex-exceptional items) — derived
	20.7	21.2
	16.7	16.8
	₹2.51	₹2.49

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

GKSL₹171.87

Gujarat Kidney And Super Speciality Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersGPTHEALTH SHALBY INDRAMEDCO LOTUSEYE ARTEMISMED DRAGARWQ KMCSHIL KOVAIMcap ₹1,355 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	82.0	101.0
Other Income	0.9	1.6
Total Income	82.9	102.6
Expenses
+ Cost of Materials Consumed	9.1	12.1
+ Employee Benefit Expense	13.6	16.8
+ Finance Costs	1.9	2.4
+ Depreciation & Amortisation	4.7	5.2
+ Other Expenses	32.3	45.4
Total Expenses	61.7	81.9
EBITDA	26.9	26.7
EBIT	22.2	21.5
Profit
PBT before Exceptional Items	21.2	20.7
Pretax Income	21.2	20.7
+ Current Tax	5.2	4.8
+ Deferred Tax	-0.8	-0.9
Tax Expense	4.4	4.0
Net Income	16.8	16.7
+ Net Income — Continuing Ops	16.8	16.7
+ Other Comprehensive Income	-0.0	0.2
Total Comprehensive Income	16.8	16.9
Net Income to Common	15.5	15.8
Minority Interest	1.3	1.3
Per Share
Basic EPS	2.49	2.51
Diluted EPS	2.49	2.51
Other Comprehensive Income — detail
+ Other Comprehensive Income	-0.0	0.2
+ Items NOT to be Reclassified to P&L	0.1	—
+ Tax on Items NOT to be Reclassified	0.1	0.0
Comprehensive Income — Owners of Parent	15.4	16.0
Comprehensive Income — Non-controlling Interests	1.3	1.3
Per Share — as-filed variants
Basic EPS — Continuing Operations	2.49	2.51
Diluted EPS — Continuing Operations	2.49	2.51
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	72.9	89.0
Gross Margin %	88.89	88.06
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	21.2	20.7
Net Income Adj (tax-effected)	16.8	16.7
EPS Adj	2.49	2.51
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00
Filed Debt Equity	0.06	—
Filed Iscr	47.93	—
Paid Up Equity Capital	15.8	15.8

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.